LG Chem LUCON® TX5007, the Engineering Plastic Used for Electrostatic Powder Coating Is Now Applied to Japanese Global OEM’s Front Fenders
10.1.2023 02:00:00 EET | Business Wire | Press release
LG Chem (KRX: 051910) has started supplying engineering plastics to Mitsubishi Motors for its powder coating parts used as the front fenders of RVR, Delica D:5 and Outlander models.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230103005882/en/
RVR (Photo: Business Wire)
Front fender is located on the side of the vehicles, which not only acts as one of key factors in the exterior design but also protects its wheels from road debris. Thus, it not only should possess a high level of mechanical robustness but also an excellent exterior quality to keep a high integrity design with the rest of the car body.
LUCON TX5007 developed by LG Chem is a compound material that combines modified polyphenylene ether (mPPE) and polyamide (PA66) alloy with carbon nanotubes (CNTs), and has an excellent electrical conductivity and show strong mechanical properties. In addition, this product has an outstanding heat resistance, making it suitable for the automotive on-the-line painting process at 200 °C or higher. At the same time, it also provides an excellent dimensional stability thanks to its low coefficient of linear thermal expansion (CLTE).
In general, applying plastics instead of steel/aluminum contributes to automotive light weight. When a plastic fender is used, the weight of the vehicle is reduced by about 4 kg, which also improves fuel efficiency. Furthermore, plastic fenders can provide other benefits, such as reduced fuel exhaust emissions and carbon footprints.
In addition to LUCON TX5007, LG Chem has a broad portfolio of products that can be used for large-scale automotive exterior parts that need to utilize powder coating process. These products can be customized to meet automotive suppliers’ diverse parts requirements for fenders, bumper panels, hoods, tailgates, fuel doors, and side mirrors.
At the same time, LG Chem is using CNT, a filler that produces excellent conductivity even with a small amount in its engineering plastics to support diverse requirements of customers. Since this material can cover a wider range of electrical conductivity compared to other carbon fillers such as Carbon Black and Carbon Fiber, it is considered an optimal solution for powder coating. LG Chem has not only built its own CNT production line, but now expanding its 4th plant for a mass production in 2024, for the reliable supply of high-quality products for powder coating.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230103005882/en/
Contact information
LG Chem, Ltd.
Sangkuhn Sung, Manager
+82-2-3773-5136
sungsk@lgchem.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom